M. Babaoglu Et Al. , "Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists," CLINICAL PHARMACOLOGY & THERAPEUTICS , vol.78, no.6, pp.619-626, 2005
Babaoglu, M. Et Al. 2005. Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. CLINICAL PHARMACOLOGY & THERAPEUTICS , vol.78, no.6 , 619-626.
Babaoglu, M., Bayar, B., Aynacioglu, A., Kerb, R., Abali, H., Celik, I., ... Bozkurt, A.(2005). Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. CLINICAL PHARMACOLOGY & THERAPEUTICS , vol.78, no.6, 619-626.
Babaoglu, MO Et Al. "Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists," CLINICAL PHARMACOLOGY & THERAPEUTICS , vol.78, no.6, 619-626, 2005
Babaoglu, MO Et Al. "Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists." CLINICAL PHARMACOLOGY & THERAPEUTICS , vol.78, no.6, pp.619-626, 2005
Babaoglu, M. Et Al. (2005) . "Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists." CLINICAL PHARMACOLOGY & THERAPEUTICS , vol.78, no.6, pp.619-626.
@article{article, author={MO Babaoglu Et Al. }, title={Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists}, journal={CLINICAL PHARMACOLOGY & THERAPEUTICS}, year=2005, pages={619-626} }